Inventor
AREND MICHAEL P
US35 patents
⚠️ This page may combine multiple inventors who share the name “AREND MICHAEL P”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
FIBROGEN INC
27 patentsUS7323475B2Jan 29, 2008
Nitrogen-containing heteroaryl compounds and methods of use thereof
FIBROGEN INC97 citations98
US7863292B2Jan 4, 2011
Nitrogen-containing heteroaryl compounds and methods of use thereof
FIBROGEN INC28 citations96
US7629357B2Dec 8, 2009
Nitrogen-containing heteroaryl compounds and methods of user thereof
FIBROGEN INC38 citations96
US8017625B2Sep 13, 2011
Nitrogen-containing heteroaryl compounds and methods of use thereof
FIBROGEN INC42 citations94
US7696223B2Apr 13, 2010
Pyrrolo- and Thiazolo-pyridine compounds, and methods of use thereof
FIBROGEN INC54 citations94
US9339527B2May 17, 2016
Nitrogen-containing heteroaryl compounds and methods of use thereof
FIBROGEN INC7 citations92
US8883823B2Nov 11, 2014
Crystalline forms of a prolyl hydroxylase inhibitor
FIBROGEN INC20 citations92
US8765956B2Jul 1, 2014
Nitrogen-containing heteroaryl compounds and methods of use thereof
FIBROGEN INC19 citations92
US10092558B2Oct 9, 2018
Nitrogen-containing heteroaryl compounds and methods of use thereof
FIBROGEN INC3 citations84
US9708269B2Jul 18, 2017
Process for making isoquinoline compounds
FIBROGEN INC6 citations84
US9617218B2Apr 11, 2017
Crystalline forms of a prolyl hydroxylase inhibitor
FIBROGEN INC5 citations84
US9371288B2Jun 21, 2016
Crystalline forms of a prolyl hydroxylase inhibitor
FIBROGEN INC7 citations84
US9340511B2May 17, 2016
Process for making isoquinoline compounds
FIBROGEN INC16 citations84
US9115085B2Aug 25, 2015
Crystalline forms of a prolyl hydroxylase inhibitor
FIBROGEN INC12 citations84
US9000006B2Apr 7, 2015
Thienopyridine compounds, and methods of use thereof
FIBROGEN INC7 citations84
US10927081B2Feb 23, 2021
Enhanced erythropoiesis and iron metabolism
FIBROGEN INC3 citations83
US9695170B2Jul 4, 2017
Naphthyridine derivatives as inhibitors of Hypoxia inducible factor (HIF) hydroxylase
FIBROGEN INC5 citations83
US9271970B2Mar 1, 2016
Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase
FIBROGEN INC7 citations83
US10272078B2Apr 30, 2019
Crystalline forms of a prolyl hydroxylase inhibitor
FIBROGEN INC2 citations73
US10118897B2Nov 6, 2018
Crystalline forms of a prolyl hydroxylase inhibitor
FIBROGEN INC2 citations73
US9918977B2Mar 20, 2018
Crystalline forms of a prolyl hydroxylase inhibitor
FIBROGEN INC3 citations73
US9643928B2May 9, 2017
Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
FIBROGEN INC4 citations73
US11680047B2Jun 20, 2023
Enhanced erythropoiesis and iron metabolism
FIBROGEN INC1 citations72
US9409892B2Aug 9, 2016
4-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitors
FIBROGEN INC6 citations71
US9387200B2Jul 12, 2016
Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
FIBROGEN INC5 citations71
US11229637B2Jan 25, 2022
Nitrogen-containing heteroaryl compounds and methods of use thereof
FIBROGEN INC0 citations62
US10646482B2May 12, 2020
Nitrogen-containing heteroaryl compounds and methods of use thereof
FIBROGEN INC0 citations52
AREND MICHAEL P
4 patentsUS8916585B2Dec 23, 2014
Nitrogen-containing heteroaryl compounds and methods of use thereof
AREND MICHAEL P16 citations92
US8759373B2Jun 24, 2014
Cyanoisoquinoline compounds and methods of use thereof
AREND MICHAEL P21 citations92
US8278325B2Oct 2, 2012
Nitrogen-containing heteroaryl compounds and methods of use thereof
AREND MICHAEL P22 citations92
US8269008B2Sep 18, 2012
Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions
AREND MICHAEL P37 citations91